Navigation Links
EGEN, Inc. Advances a Systemically Delivered RNAi Therapeutic for the Treatment of Pulmonary Arterial Hypertension (PAH)
Date:6/5/2013

HUNTSVILLE, Ala., June 5, 2013 /PRNewswire/ -- EGEN, Inc., a clinical stage biopharmaceutical  company, announced today that  EGEN's proprietary lung targeting Staramine-mPEG nanoparticle delivery system has been used to administer an inhibitor of microRNA-145 (anti-miRNA-145) in a rat model of severe occlusive PAH.  Treatment was shown to significantly reverse the pulmonary hypertension associated with the advanced stages of the disease and restore cardiovascular function.  This program, in collaboration with Dr. William Gerthoffer at the University of South Alabama College of Medicine, is focused on evaluating new approaches that can be used to prevent vascular remodeling that occurs in patients with PAH which leads to the deleterious cardiovascular effects associated with the disease.  The results of this work were recently presented at the 2013 American Thoracic Society Annual Meeting held in Philadelphia, PA.  The abstract titles were:  "Targeted Pulmonary Delivery of a microRNA Inhibitor Reverses Severe Pulmonary Arterial Hypertension in Rats", J.M. Mclendon presenting author, and "Treatment with Anti-microRNA in an Experimental Model of Occlusive Pulmonary Arterial Hypertension Reverses Vascular Remodeling", S.R Joshi presenting author.

MicroRNAs (miRNAs) are endogenously produced non-coding RNAs that bind to partially complimentary target sites in messenger RNA leading to degradation of transcript or translation inhibition.  In this way, miRNAs can post-transcriptionally regulate gene expression in a cell.  Increasingly, it is being recognized that miRNA disregulation may be the root cause of many diseases.  In PAH, an increase in one particular miRNA (miRNA-145) has been linked to pulmonary vascular remodeling.  Thus, it has been hypothesized that inhibiting the miRNA with an anti-miR (an oligonucleotide that targets miRNA) will slow or reverse established PAH-related vascular remodeling and restore normal pulmonary function.  EGEN's Staramine-mPEG nanoparticle delivery system overcomes delivery challenges by targeting the site of the miRNA-145 expression; namely the lung.

"Our approach may provide a potential breakthrough in the treatment of PAH because of the strong mechanistic linkages between up regulation of  miRNA-145 that we are targeting and the vascular remodeling associated with the disease," said Dr. William Gerthoffer , Professor and Chair, Biochemistry & Molecular Biology, University of South Alabama College of Medicine.  "Use of the Staramine-mPEG delivery system is a natural fit for this anti-miR approach where targeted delivery to the lung is a requirement."

"There is a clear unmet medical need for novel agents that can treat PAH," said Jason Fewell , Ph.D., VP of Preclinical Research and Development at EGEN, Inc. "We have been very encouraged by the positive efficacy results that have been achieved by Dr. Gerthoffer's group in their rat PAH model using our proprietary delivery technology and believe that targeting miRNAs has tremendous potential as a novel therapeutic for this devastating disease."

About PAH

PAH is a progressive, symptomatic, and ultimately fatal disorder that results from a proliferation of the smooth muscle cells that line the arteries in the lung and is characterized by high blood pressure in the arteries of the lungs.  As the arteries narrow the arterial pressure is increased and blood flow from the heart to the lungs is decreased.  To compensate, the heart must pump harder, causing the walls on the right side of the heart to thicken and weaken.  These changes make it difficult for the heart to push blood through the arteries and into the lungs. Ultimately the heart becomes so weak that it can't pump enough blood to the lungs which can ultimately cause heart failure.  Currently there are not cures for this disease only treatments that improve the management of symptoms.

About EGEN, Inc.

EGEN, Inc. (EGEN), with laboratories and headquarters in Huntsville, Alabama, is a privately held clinical stage biopharmaceutical company focused on developing therapeutics for the treatment of human diseases.  The Company specializes in the delivery of therapeutic nucleic acids (DNA and RNAi) aimed at specific disease targets.  The Company has significant intellectual property positions in synthetic carriers, their combination with oligonucleotides, expression vectors and their therapeutic applications. EGEN has research pipeline products aimed at the treatment of various cancer and cardiovascular indications and has collaborations with outside investigators, biotech organizations, and universities on various projects in these areas.

Safe Harbor for Forward Looking Statements

Certain statements contained in this press release may be deemed to be forward looking statements under federal securities laws and EGEN intends that such forward looking statements be subject to the safe harbor created thereby.  EGEN does not undertake an obligation to publicly update or revise any forward looking statements, whether as a result of new information, future events or otherwise. Actual events or results may differ from our expectations as a result of a number of factors, including but not limited to uncertainties in clinical trials and product development programs, ability and success level of the Company in securing adequate capital for operations, market place acceptance of any resulting product and other factors common to biotechnology research and development.  There can be no guarantee that any product in our pipeline will be successfully developed. 


'/>"/>
SOURCE EGEN, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Novartis Highlights Advances for Patients With Breast Cancer and Hematological Diseases With Over 160 SABCS and ASH Abstracts
2. Nabsys to Present DNA Sequence Data from Solid-State Nanodetectors at the Annual Advances in Genome Biology and Technology (AGBT) Meeting and the EMBL Omics and Personalized Health Conference
3. UWM discovery advances graphene-based electronics
4. Next-generation nanoelectronics: A decade of progress, coming advances
5. New metamaterial practical for optical advances
6. Biodetection 2012 Conference Brings Together Leading Organizations from Around the World to Address Challenges & Technology Advances in Detection and Identification of Biological Threats in Washington, DC from June 28-29, 2012
7. New Annual US$3 Million Fundamental Physics Prize Recognizes Transformative Advances in the Field
8. VisionGate Reports Advances In Its Cell-CT(TM) Automated 3D Cell Analysis Platform At ASC 2012 Scientific Meeting
9. Collegiate Inventors Honored for Innovative Science and Technology Advances
10. Computer memory could increase fivefold from advances in self-assembling polymers
11. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... ... 2016 , ... Thailand’s Board of Investment’s New York office, ... Located at booth number 7301, representatives from the Thai Government, research organizations, and ... biotechnology and life sciences sector. , Deputy Secretary General of the Thailand ...
(Date:5/25/2016)... Md. (PRWEB) , ... May 25, 2016 , ... ... request for information (RFI) issued by the Office of the National Coordinator for ... patient experience, and determines if clinically relevant data were available when and where ...
(Date:5/25/2016)... ... 2016 , ... Lady had been battling arthritis since the age of two ... knee. Lady’s owner Hannah sought the help of Dr Jeff Christiansen of Superior ... cruciate ligament and help with the pain of Lady’s arthritis. Dr Christiansen suggested that ...
(Date:5/24/2016)...   MedyMatch Technology Ltd ., the data analytics healthcare ... support tools in the emergency room, announced today that it ... Technology Industries (IATI) BioMed Conference. The Conference ... National Life Sciences and Technology Week, and is being held ... Tel Aviv, Israel . Gene Saragnese ...
Breaking Biology Technology:
(Date:5/12/2016)... May 12, 2016 WearablesResearch.com , a ... the overview results from the Q1 wave of its ... wave was consumers, receptivity to a program where they ... a health insurance company. "We were surprised ... says Michael LaColla , CEO of Troubadour Research, ...
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
Breaking Biology News(10 mins):